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1. Introduction
Malignant mesothelioma is a tumour which arises from mesothelial or possibly more primitive
sub-mesothelial cells. It occurs most commonly in the pleura, but also in the peritoneum and rarely
in the pericardium or tunica vaginalis testis [1]. The vast majority of cases (almost 80%) arise from
the pleural mesothelium, and of these, most (60-70%) are associated with asbestos exposure [2].
The first clear evidence of a causal link between asbestos exposure and primary malignant tumours
of the mesothelium was the observation by Wagner et al. (1960) of 33 cases of pleural mesothelio‐
ma in the Northwest Cape Province of South Africa, 28 in individuals who had lived close to the
crocidolite mines, mostly as children [3]. Subsequent studies, especially work by Selikoff and
associates (1965) and Whitwell and Rawcliffe (1971) in the United States, confirmed that asbes‐
tos exposure was the major risk factor for malignant pleural mesothelioma [4–6]. The epidemiol‐
ogy of malignant pleural mesothelioma is now well understood, but its biological behavior
remains an enigma and the treatment of this cancer is still controversial.
2. Incidence
The incidence of malignant pleural mesothelioma was increasing and reached a peak in the
years 2000-2005 in the United States, because of the large number of individuals who were
exposed to asbestos during the 1930s to 1960s in asbestos mines and asbestos-related indus‐
tries, before the causal relationship between asbestos and malignant pleural mesothelioma was
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recognized [7]. The recent decline in incidence is attributable to declining asbestos exposure,
and this trend is expected to continue [2]. On the other hand, asbestos use in Western Europe
remained high until 1980, and substantial quantities are still used in several European
countries. Peto et al. suggested that for the period 1995–2029 the number of men dying from
mesothelioma in Western Europe each year will almost double over the next 20 years, from
5,000 in 1998 to about 9,000 around 2018, and then decline, with a total of about a quarter of a
million deaths over the next 35 years [8]. The highest risk will be suffered by men born around
1945–50, of whom about 1 in 150 will die of mesothelioma. These projections are based on the
fit of a simple age and birth cohort model to male pleural cancer mortality from 1970 to 1989
for six countries (Britain, France, Germany, Italy, The Netherlands and Switzerland) which
together account for three-quarters of the population of Western Europe [8]. According to
Surveillance, Epidemiology and End Results (SEER) Program data, the incidence of malignant
mesothelioma in the United States is estimated to be between 1-2/million in states with minimal
exposure to mineral fibers and 10-15/million in states where large amounts of asbestos were
used [9]. The latest data available show that malignant mesothelioma is responsible for
approximately 3,000 deaths per year in the United States and an additional 5,000 deaths in
Western Europe [10], [11]. The latency period, which is the interval between first exposure and
the development of malignant mesothelioma, ranges from about 25 to 71 years and appears
to be influenced by the amount of exposure, because workers in trades with higher amounts
of exposure may experience shorter latencies compared to those exposed to lower amount of
asbestos [11], [12]. It is of crucial importance for the Thoracic Surgeons to be fully informed
about malignant pleural mesothelioma in order to reach the correct diagnosis and recommend
the appropriate treatment when dealing with it.
3. Epidemiology
The main risk factor in developing malignant mesothelioma is asbestos exposure [13]. Asbestos
refers collectively to a group of naturally occurring hydrated mineral silicate fibers that include
two major forms: serpentine, represented by chrysotile (white asbestos); and the amphiboles,
including crocidolite (blue asbestos), amosite (brown asbestos), anthophyllite, actinolite and
tremolite [13], [14]. Crocidolite fibers are regarded as the most oncogenic type of asbestos because
they are long and thin, and are believed to persist longer in the pleura, but the exact way in which
asbestos induces the development of malignant mesothelioma is still not well understood [13],
[14]. Inflammation appears to play a critical role as following asbestos exposure in vivo, recruit‐
ment of mononuclear phagocytes (which differentiate into macrophages that in turn phagocy‐
tize asbestos) was observed, resulting in the release of tumour necrosis factor-alpha (TNF-a) by
the phagocytes and mesothelial cells [14]. Exposure to asbestos can also lead to the accumula‐
tion of DNA damage in mesothelial cells through interaction with reactive nitrogen and oxygen
species, which coupled to the activation of the NF-kB pathway by TNF-a perpetuates the survival
of the DNA-damaged mesothelial cells [14–16].
Crocidolite asbestos is found only in South Africa and Western Australia but has been exported
all over the world for various industrial uses [17]. Chrysotile accounts for 97% of worldwide
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asbestos production and has been mined principally in Russia, Canada (Quebec Province),
South Africa, Italy, and Cyprus [17]. Chrysotile itself is not thought to cause malignant pleural
mesothelioma but is often contaminated with amphibole fibers, such as tremolite or amosite
[18], [19]. However, the issue of chrysotile as a cause of malignant mesothelioma remains still
controversial [17–19].
Individuals can be exposed to asbestos in many situations because of its widespread use [17],
[20]. However, the areas of the world that have a high incidence of malignant pleural meso‐
thelioma are those with asbestos mines and countries that have shipyards, insulation, con‐
struction, and automobile industries that use large amounts of asbestos [17], [21–23].Regarding
tobacco use, there is no evidence that smoking increases the risk of development of malignant
mesothelioma [1], [24]. On the other hand, past radiotherapy is considered as a risk factor from
case series [1], [25].
4. Biological behavior
The right pleural cavity is more commonly involved than the left. In the early stages of the
disease, the tumour often appears as multiple nodules on the surface of the visceral and parietal
pleurae [1]. Occasionally, a localized pleural mass may develop but more often the nodules
coalesce to form a sheet of tumour which surrounds the lung, extends along the fissures and
may invade the underlying parenchyma [1]. Pericardial and diaphragmatic invasion are
common. Bronchial invasion, usually by spread from the pleura near the hilum, is uncommon
and may lead to diagnostic confusion if tumour is visible at bronchoscopy [26]. At post-mortem
examination, distant metastases are common, occurring in about two-thirds of the cases with
sarcomatoid type and one-third of the patients with the epithelioid and mixed types [26].
Diffuse malignant mesothelioma is divided into three main histological types: epithelioid
which is most common, sarcomatoid and mixed or biphasic. The epithelial variety displays
several patterns including tubulopapillary and glandular [1]. Histochemical and immunohis‐
tochemical stains assist in differentiating epithelioid mesothelioma from adenocarcinoma, the
most common and difficult differential diagnosis [27].
A small number of localized serosal/subserosal neoplasms with histopathologic, histochemi‐
cal, immunohistochemical, and ultrastructural features identical to those of diffuse malignant
mesothelioma have been described and given the designation ‘‘localized malignant mesothe‐
lioma’’ [28]. Crotty et al first described a series of 6 localized malignant mesotheliomas in 1994
[28]. Localized malignant mesotheliomas are extremely rare solitary circumscribed nodular
tumors, attached either in a sessile or pedunculated manner to the surface of the pleura [29].
Most localized malignant mesotheliomas present as incidental findings or with nonspecific
symptoms. Epithelial-type localized malignant mesotheliomas predominate, and very few
tumors are purely sarcomatous [29]. However, as opposed to ordinary diffuse malignant
mesotheliomas where epithelial forms have a better prognosis than sarcomatous forms and
biphasic forms are intermediate, histologic subtype does not correlate with survival [29].
Tumor size also does not appear to affect the clinical course [28]. Because of the vastly different
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treatment and prognosis, it is crucial to separate localized malignant mesotheliomas from
diffuse malignant mesotheliomas. Diffuse malignant mesotheliomas always show gross and/
or microscopic evidence of widespread tumor on the serosal surface, as individual tumor
nodules, or as a rind around viscera or as tumor caking [29]. Recurrent spread of localized
malignant mesothelioma in the manner of diffuse malignant mesothelioma has been reported
[30]. The crucial feature of localized malignant mesothelioma is that many cases can apparently
be cured by surgical excision [29]. Localized malignant mesotheliomas should be separated
from diffuse malignant mesotheliomas because of their localized presentation, quite different
biologic behavior, and far better prognosis.
5. Clinical presentation
The majority of cases occur in men, reflecting their greater frequency of occupational asbestos
exposure. A careful occupational history should be taken when mesothelioma is suspected or
confirmed [1]. Median age at presentation is in the seventh decade but the disease may occur
at any age [31]. During the early stages of disease, dyspnea is the predominant symptom and
is related to the presence of an effusion. When the effusion is drained, patients are asympto‐
matic [17], [32]. As the tumor grows, patients develop ill-defined, mild, but continuous chest
discomfort. Dyspnea may actually improve during this phase of the disease because, with
tumor growth, the pleural surfaces fuse and the effusion resolves [17], [33]. Only when the
disease becomes locally advanced does the patient develop severe chest pain, which is related
to tumor infiltration of the chest wall and intercostal nerves [17], [33]. This is accompanied by
a sense of chest tightness and dyspnea caused by entrapment of the lung by tumor [17]. There
may be anorexia, weight loss and general malaise. Profuse sweats, particularly at night, often
occur [1]. In the final stages of disease, dyspnea and chest pain become severe and unremitting
[17]. These symptoms are related to encasement of the chest wall, lung, and mediastinum, and
are occasionally associated with mediastinal shift and compression of the contralateral lung
[17], [32]. Subcutaneous nodules may develop, particularly at sites of previous pleural
aspiration or biopsy [1]. Other late features may include superior vena caval obstruction,
pericardial tamponade due to malignant effusion or pericardial constriction due to tumour
invasion of the pericardium [1], [32]. The tumour may spread to the abdominal cavity causing
ascites. Mesothelioma may metastasize widely to all areas including the contralateral pleura
and lung, intra- and extra-thoracic lymph nodes, liver, bone and brain [1], [26].
6. The role of biomarkers in early detection of malignant pleural
mesothelioma and in predicting patients’ response after therapy and
outcome
Because of mesothelioma’s nonspecific presenting symptoms, patients often suffer a substan‐
tial diagnostic delay, resulting in a more advanced disease at diagnosis [34]. At present, the only
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instruments for screening and diagnosis are based on radiological tests, posing evident econom‐
ic and radio-protectionist problems [35]. An adequate screening program and subsequent earlier
detection might improve patient outcome [36]. Current guidelines on mesothelioma manage‐
ment do, however, not advocate the use of screening and recommend that the efficacy of any
screening tool should be further evaluated in high-risk populations [37]. Soluble mesothelin (SM)
and megakaryocyte potentiating factor (MPF) are serum biomarkers of mesothelioma [38], [39].
Mesothelin is a 40 kDa cell surface glycophosphatidylinositol- anchored protein expressed at a
low level by normal mesothelial cells in the pleura, peritoneum, and pericardium. It is highly
expressed in pancreatic cancer, ovarian cancer, mesotheliomas, and some other cancers [40].
Hollevoet et al. showed that the longitudinal behavior of SM and MPF in controls indicates that a
biomarker-based screening approach can benefit from the incorporation of serial measure‐
ments and individual-specific screening rules, adjusted for age and glomerular filtration rate
(GFR) in their prospective longitudinal cohort study in asbestos-exposed individuals [34]. Large-
scale validation remains nevertheless mandatory to elucidate whether such an approach can
improve the early detection of mesothelioma [34].
Other authors are evaluating different combination of biological indicators as screening and
early diagnosis markers, such as plasma osteopontin (pOPN) and serum soluble mesothelin-
related peptides (SMRP) [35]. OPN is a glycoprotein overexpressed in several human neo‐
plasms such as lung, breast, and colon cancer [41]. OPN modulates cell-matrix interactions;
high levels correlate with tumor invasion, progression, and metastasis [35]. Serum OPN
(sOPN) levels in patients with malignant pleural mesothelioma have been reported to be
higher than in healthy subjects [42], [43]. Cristaudo et al. showed for the first time that
combined SMRP and pOPN measurements can increase both sensitivity and specificity, in
diagnosis of epithelioid malignant pleural mesothelioma, in terms of combined risk index [35].
Biomarkers are also urgently needed for the selection of patients likely to benefit from
multimodality therapy regimens while preventing aggressive but futile treatment interven‐
tions in ineligibles [37], [44]. Serum C-reactive protein (CRP) is known as a widely available
routine marker for diagnosis and follow-up of patients affected by various inflammatory
diseases [45]. Recently, a negative prognostic value has been assigned to elevated serum CRP
levels in several malignant diseases including breast, ovarian, renal, and lung cancer [45–49].
The results of Ghanim et al. suggest that multimodality regimens including radical resection
increase survival selectively in malignant pleural mesothelioma patients with normal pre‐
treatment serum CRP levels, in their retrospective multicenter analysis [50].
The last few years there is an increased focus on markers of resistance, which can be used to
predict treatment efficacy and thereby guide treatment decisions. Cisplatin and carboplatin
work by binding to the DNA forming adducts that lead to intra- or interstrand cross-links. The
formation of these DNA cross-links inhibits the cell from replicating and drives it toward
apoptosis. This proapoptotic signal can be counteracted by the cells’ intrinsic ability to
recognize and repair the DNA damage. Nucleotide excision repair is a highly conserved
pathway that maintains DNA integrity by removing helix-distorting cross-links. This pathway
seems to be a key element in mediating resistance toward platinum compounds. There are
three important steps in this pathway. First, the DNA damage is recognized then excised, and
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finally, the excised area is resynthesized. Excision repair cross-complementation group 1
enzyme (ERCC1) plays a rate-limiting step in this process by forming a complex with xero‐
derma pigmentosum complementation group F that excises the damaged DNA [51–54]. Two
studies have recently addressed the possible predictive and prognostic role of ERCC1 in
malignant pleural mesothelioma [51]. In an observational study by Righi et al., immunohis‐
tochemistry was used to detect ERCC1 in a cohort of 45 malignant pleural mesotheliomas
treated with different platinum-based therapies (cisplatin-pemetrexed or carboplatin-peme‐
trexed in different regimens) [55]. In this series, there was no association between ERCC1 status
and treatment response, but the authors did find high ERCC1 levels to be associated with a
better prognosis regardless of the chemotherapy regimen used [51], [55]. Zucali et al. also used
immunohistochemistry to detect ERCC1 in a retrospective cohort of 67 malignant pleural
mesotheliomas treated with a combination of pemetrexed and carboplatin [56]. These authors
found no association between ERCC1 protein status and clinical outcome in terms of disease
control, progression-free survival and overall survival [51], [56]. The retrospective study of
Zimling et al. in malignant pleural mesothelioma patients treated with cisplatin/vinorelbine
suggests that low ERCC1 expression, evaluated by immunohistochemistry, may predict longer
progression-free survival, a result that warrants further validation [51].
7. Staging
Because of the lack of a universally accepted staging system, the International Mesothelioma
Interest Group (IMIG) developed an internationally accepted staging system that was based
on the available data correlating clinical and pathologic extent of disease with outcome [57].
The IMIG staging system has become universally accepted and adopted by the UICC and the
AJCC. [17] This is based upon a TNM (tumour, node, metastasis) system (Tables 1 and 2) [57].
Information regarding the degree of visceral and parietal pleural involvement often requires
the use of diagnostic thoracoscopy by means of VATS (Video Assisted Thoracic Surgery). Chest
CT may also be helpful.
Cervical mediastinoscopy as a pre-operative invasive mediastinal staging tool remains still a
debating issue. The high rate of false negative results or the presence of disease in lymph nodes
inaccessible by mediastinoscopy, are the main reasons for its limited role in the staging
algorithm [58]. Pilling et al. suggested the use of cervical mediastinoscopy as a selection tool
in order to identify the patients who would benefit most from extrapleural pneumonectomy
as nodal size on CT is an unreliable marker of malignancy [59]. Lately, it has been proposed
that cervical mediastinoscopy should be used as routine method of prognostic staging in all
patients undergoing radical surgery for malignant pleural mesothelioma [60].
Positron emission tomography (PET) scan has a crucial role in thoracic oncology due to its
impact on diagnosis, staging and prognosis [61]. PET is useful diagnostic tool to identify and
stage malignant pleural mesothelioma and differentiate it from benign pleural disease. Its
impact in the prediction of survival, determination of mortality risk and detection of metasta‐
ses and recurrent disease is considered valuable. However, the combination of PET-CT can
produce superior diagnostic results than PET alone [62].
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T1 T1a Tumour limited to the ipsilateral parietal pleura, including mediastinal and diaphragmatic pleura. No
involvement of the visceral pleura
T1b Tumour involving the ipsilateral parietal pleura, including mediastinal and diaphragmatic pleura.
Scattered foci of tumour also involving the visceral pleura
T2 Tumour involving each of the ipsilateral pleural surfaces (parietal, mediastinal, diaphragmatic and visceral
pleura) with at least one of the following features:
Involvement of diaphragmatic muscle
Confluent visceral pleural tumour (including the fissures) or extension of tumour from visceral pleura into
the underlying pulmonary parenchyma
T3 Describes locally advanced but potentially resectable tumour. Tumour involving all of the ipsilateral pleural
surfaces (parietal, mediastinal, diaphragmatic and visceral) with at least one of the following features:
Involvement of the endothoracic fascia
Extension into the mediastinal fat
Solitary completely resectable focus of tumour extending into the soft tissues of the chest wall
Non-transmural involvement of the pericardium
T4 Describes locally advanced technically unresectable tumour. Tumour involving all of the ipsilateral pleural
surfaces (parietal, mediastinal, diaphragmatic and visceral) with at least one of the following features:
Diffuse extension or multifocal masses of tumour in the chest wall with or without associated rib destruction
Direct transdiaphragmatic extension of tumour to the peritoneum
Direct extension of tumour to the contralateral pleura
Direct extension of tumour to one or more mediastinal organs
Direct extension of tumour into the spine
Tumour extending through to the internal surface of the pericardium with or without a pericardial effusion,
or tumour involving the myocardium
N Lymph nodes
NX Regional lymph nodes cannot be assessed
N0 No regional lymph node metastases
N1 Metastases in the ipsilateral bronchopulmonary or hilar lymph nodes
N2 Metastases in the subcarinal or the ipsilateral mediastinal lymph nodes including the ipsilateral internal
mammary nodes
N3 Metastases in the contralateral mediastinal, contralateral internal mammary, ipsilateral or contralateral
supraclavicular lymph nodes
M Metastases
MX Presence of distant metastases cannot be assessed
M0 No distant metastasis
M1 Distant metastasis present
Table 1. New International Staging System for Malignant Pleural Mesothelioma (IMIG): TNM staging (Rusch VW).
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Stage Description
Stage I
Ia T1aN0M0
Ib T1bN0M0
Stage II T2N0M0
Stage III Any T3M0
Any N1M0
Any N2M0
Stage IV Any T4
Any N3
Any M1
Table 2. New International Staging System for Malignant Pleural Mesothelioma (IMIG): Clinical staging (Rusch VW).
8. Surgical treatment
Malignant pleural mesothelioma is a disease that is difficult to be cured. But efforts made,
combining various medical specialties such as thoracic surgery, oncology, radiotherapy and
pulmonology, to the greatest possible therapeutic approach. In this chapter, the goal is,
through the review of contemporary literature, to highlight the modern surgical strategy for
treatment of malignant pleural mesothelioma.
Based on the clinical staging of disease and histological type, the treatment strategy should be
decided. Specifically, for clinical stage I-III or epithelioid or mixed histology type, the proposed
treatment is surgical or combined, whereas for clinical stage IV or sarcomatoid histology type,
chemotherapy is suggested [63].
In case that surgical treatment has been chosen, the patient should undergo a careful preop‐
erative evaluation, that includes the following selection criteria [64]:
• Performance status 0 – 1
• Predicted postoperative FEV1 > 1.0 L
• Room air PaO2 > 65 mmHg
• Room air PaCO2 < 45 mmHg
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• Ejection fraction > 40%
• Mean pulmonary artery pressure < 30 mmHg
The  aim  of  surgical  treatment  is  to  achieve  the  maximum  cytoreduction  and  radical
resection of macroscopic lesions of the disease and includes the following approaches [65]:
• Extrapleural pneumonectomy
• Pleurectomy - Decortication
• Pleurectomy - Decortication and Hyperthermic Pleural ChemoPerfusion / Photodynamic
Therapy
9. Extrapleural pneumonectomy
The extrapleural pneumonectomy involves radical excision of the entire lung, en block with
the parietal pleura, including the ipsilateral hemidiaphragm and pericardium and radical
mediastinal lymph node dissection. The main goal of this surgical technique is to achieve
complete exclusion of macroscopic disease [66].
The  surgical  technique  is  usually  applied  with  posterolateral  thoracotomy.  In  case  of
previous incisions (probably for  biopsy),  all  scars  should be excluded in order to avoid
spreading  the  disease.  Entry  into  the  thoracic  cavity  is  usually  made through the  sixth
intercostal space. To achieve good surgical field, the sixth rib may be excised or a second
thoracotomy must be performed below in order to facilitate better resection and reconstruc‐
tion of the hemidiaphragm. After division of the intercostal space, an extrapleural plan is
created separating the parietal  pleura from endothoracic  fascia,  carefully,  without enter‐
ing  the  pleural  cavity.  Usually  we  begin  with  blunt  and  sharp  dissection  caudal-to-
cephalad. Particular attention is required during the preparation of parietal pleura to the
anatomical area of internal mammary vessels, azygos vein, aorta, esophagus, superior vena
cava,  inferior vena cava and mediastinum. The pericardium is  opened and explored for
possible metastases and eventually is resected. The hemidiaphragm is resected with very
careful  dissection  from  the  peritoneum,  without  entering  the  peritoneal  cavity.  Then  a
complete mediastinal lymphadenectomy is carried out and ligation of major thoracic duct.
Finally in order to complete pneumonectomy, pulmonary artery and veins as well as the
main bronchus are ligated.  The deficit  of  the pericardium is  restored by placing bovine
pericardium,  while  hemidiaphragm defect  restored with synthetic  mesh.  Finally  place  a
chest  tube,  followed by closure  of  the  wound in  accordance  with  the  anatomical  struc‐
tures' class [64], [67].
The complications of this surgical procedure are represented in the table 3 below:
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Common Complications Unommon Complications
Hemothorax Bronchopulmonary fistula
Atrial arrhythmias Patch dehiscence
Cardiac tamponade Empyema
Cardiac hernia ARDS
Chylothorax Pneumonia
Abdominal organs herniation Septicemia
Postpneumonectomy Vocal cord palsy
pulmonary edema Horner's syndrome
Table 3. Complications of extrapleural pneumonectomy
Results obtained from the most recent studies show that the rate of perioperative complications
ranges in 50 - 68 %, while the mean overall survival of patients receiving combination therapy
which includes extrapleural pneumonectomy ranges 12,8 - 29,1 months (table 4) [68–74].
Surgical
Technique
Study
Group
Publication
Year
Patient
Population
Median
Overall
Survival
(months)
Complications
(%)
EPP Bille et al 2012 25 12,8 68
EPP Rena et al 2012 19 20 62
EPP Nakas et al 2012 99 14,7 68
EPP Buduhan et al 2009 46 24
EPP Hasani et al 2009 18 20,4
EPP Krug et al 2009 54 29,1
EPP Yan et al 2009 70 20 50
Table 4. Recent studies of extrapleural pneumonectomy (EPP) for the surgical treatment of mesothioma.
10. Pleurectomy - Decortication
Pleurectomy and decortication involves the surgical treatment with performance of dissection
of parietal pleura from endothoracic fascia, diaphragm and mediastinum (including the
pulmonary fissures down to the pulmonary artery and pleural reflections) and decortication
of visceral pleura (visceral pleura is peeled away from the lung like the stripping away of a
rind), with preservation of lung parenchyma (fig 1). The resection of the parietal and visceral
pleura can be partial, radical or extensive (when included excision of the pericardium and / or
hemidiaphragm) [75].
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Figure 1. Parietal and visceral pleura after pleurectomy – decortication.
This surgical procedure is usually performed by posterolateral thoracotomy at the level of the
sixth or seventh intercostal space. After opening the selected intercostal space, prepare the
parietal pleura in all directions. We should mobilize the parietal pleura to dislodge it from the
visceral pleura, where there are adhesions. In next step, visceral pleura is peeled gently away
from the lung surface including the interlobar fissures, avoiding produce tears to the under‐
lying lung. After the decortication, may proceed to parietal pleurectomy, carefully, preventing
the injury of the brachial plexus, the vagus nerve, the subclavian artery and the sympathetic
chain, the esophagus, the thoracic duct, the phrenic and recurrent nerves and hilar blood
vessels. Finally place two chest tubes, followed by closure of the wound [67].
The complications of the procedure is primarily bleeding from the detachment of parietal pleura
and the many air leaks from the detachment of visceral pleura. In recent studies, the complica‐
tion rate fluctuates between 24 - 43 %, while the mean overall survival of patients with multimo‐
dality treatment including pleurectomy - decortication ranges 13,5 - 25 months (table 5).
Surgical
Technique
Study
Group
Publication
Year
Patient
Population
Median
Overall
Survival
(months)
Complications
(%)
P/D Rena et al 2012 20 25 24
P/D Nakas et al 2012 67 13,4 43
Table 5. Recent studies of pleurectomy - decortication (P/D) for the surgical treatment of mesothioma.
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11. Pleurectomy - Decortication and hyperthermic pleural
chemoperfusion / photodynamic therapy
The later and modern surgical therapy for the treatment of malignant mesothelioma is the
combination of radical resection of parietal and visceral pleura (pleurectomy – decortication),
by applying hyperthermic pleural lavage (40–41°C), using aqueous solution containing
chemical agents such as povidone iodine or chemotherapeutic substances [76].
A newer and more advanced method is the combination of radical resection of parietal and
visceral pleura (pleurectomy – decortication), followed by continuous (30min) chemoperfu‐
sion supported by extracorporeal circulation machine, for washing the pleural cavity with
hyperthermic (40–41°C), aqueous solution containing chemotherapeutic substances (used also
for systemic chemotherapy) [77].
Specifically after pleurectomy – decortication, place two chest tubes in the pleural cavity,
ensuring that each is directed anteriorly and top and the other posteriorly and to diaphragm
nearby. Usually, the first tube tube need for inflow and the second for outflow. The tubes are
connected to a specific extracorporeal circulation machine and create a closed flow circuit,
through which the hyperthermic solution circulate and washes the pleural cavity (fig 2-4).
Figure 2. The patient is connected to the extracorporeal circulation circuit in order to apply hyperthermic pleural che‐
moperfusion.
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Figure 3. The arrow shows the direction flow of the hyperthermic solution inside the thoracic cavity.
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Figure 4. The screen of extracorporeal circulation machine showing in real time all parameters related to the proce‐
dure (temperature, flow-rate, time).
Hyperthermic pleural chemoperfusion can be combined with extrapleural pneumonectomy or
with pleurectomy – decortication. Two recent studies suggest that the combination of hyperther‐
mic pleural chemoperfusion after pleurectomy – decortication has a better median survival rate
(23 VS 20 months) and fewer complications (27,7 VS 66 %) than the combination of hyperther‐
mic pleural chemoperfusion after extrapleural pneumonectomy (table 6), [78], [79].
Surgical
Technique
Study
Group
Publication
Year
Patient
Population
Median
Overall
Survival
(months)
Complications
(%)
P/D and
hyperthermic
pleural lavage with
povidone-iodine
Lang Lazdunski et al 2012 54 23 27,7
EPP and
hyperthermic
cisplatin perfusion
Zellos et al 2009 29 20 66
Table 6. Recent studies of extrapleural pneumonectomy (EPP) or pleurectomy - decortication (P/D) in combination
with hyperthermic pleural chemoperfusion for the surgical treatment of mesothioma.
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Futhermore, hypertermic intra-thoracic chemotherapy (HITHOC) can be used even in
inoperable patients with clinical stage III-IV, with very good results, mean survival rate 30
months, because it increases the process of apoptosis [80].
Also the radical resection of parietal and visceral pleura (pleurectomy – decortication) can be
combined with the application of intracavitary photodynamic therapy [81]. The latest, relevant
studies are very few and come from the same center. They show very good median survival
rate (25 - 31,8 months) and few complications (table 7) [82], [83].
Surgical
Technique
Study
Group
Publication
Year
Patient
Population
Median
Overall
Survival
(months)
P/D - PDT Friedberg et al 2012 38 31,8
P/D - PDT Friedberg et al 2011 14 25
Table 7. Recent studies of pleurectomy - decortication (P/D) in combination with intracavitary photodynamic therapy
(PDT) for the surgical treatment of mesothioma.
The main goal of all these combined techniques is the elimination of possible microscopic
residual disease.
12. Discussion
Unfortunately, there are not too many recent studies to demonstrate clearly the most appro‐
priate and effective surgical therapy in the treatment of malignant pleural mesothelioma. The
latest studies regarding surgical treatment of malignant mesothelioma are presented in table 8.
However, some recent studies have tried to answer the question. Apparently, extrapleural
pneumonectomy has achieved greater surgically induced cytoreduction and this method was
the first surgical approach for many years [84]. Also, studies show that extrapleural pneumo‐
nectomy, when is not complicated, can have a significant and rapid, positive effect on resolu‐
tion of symptoms and improve the quality of life in patients with malignant pleural
mesothelioma [85]. It is claimed that co-removal of pericardium and hemidiaphragm should
not be applicable to extrapleural pneumonectomy, because this fact increases very much the
postoperative complications and the risk of disease seeding, without significantly increase in
mean survival [86].
However, current studies, that compare extrapleural pneumonectomy and pleurectomy –
decortication, showed that extrapleural pneumonectomy had more and larger postoperative
complications with worse quality of life, disease recurrence was delayed a little longer, while
the median survival did not show a statistically significant difference [69] [70] [87] [88]. Even
more, recent studies demonstrated that patients with pleurectomy – decortication were
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superior therapeutically to extrapleural pneumonectomy because these patients were able to
undergo even second-line chemotherapy [78].
Surgical
Technique
Study
Group
Publication
Year
Patient
Population
Radiotherapy
Systematic
Chemotherapy
Median
Overall
Survival
(months)
Complications
(%)
EPP Bille et al 2012 25 yes yes 12,8 68
EPP Rena et al 2012 19 yes yes 20 62
EPP Nakas et al 2012 99 yes yes 14,7 68
P/D Rena et al 2012 20 yes yes 25 24
P/D Nakas et al 2012 67 yes yes 13,4 43
P/D and
hyperthermic
pleural lavage
with povidone-
iodine
Lang
Lazdunski et
al
2012 54 yes yes 23 27,7
P/D
PDT
Friedberg et al 2012 38 yes yes 31,8
MEPP Friedberg et al 2011 14 8,4
P/D
PDT
Friedberg et al 2011 14 yes yes 25
EPP Buduhan et al 2009 46 yes yes 24
EPP Hasani et al 2009 18 yes yes 20,4
EPP Krug et al 2009 54 yes yes 29,1
EPP and
hyperthermic
cisplatin perfusion
Zellos et al 2009 29 20 66
EPP Yan et al 2009 70 yes yes 20 50
Table 8. All recent studies of extrapleural pneumonectomy (EPP) or pleurectomy - decortication (P/D) or/and
combination with hyperthermic pleural chemoperfusion or/and intracavitary photodynamic therapy (PDT) for the
surgical treatment of mesothelioma
The results from the application of thoracic cavity lavage with hyperthermic solution and
povidone iodide after pleurectomy – decortication, are promising and with fewer complica‐
tions compared to extrapleural pneumonectomy [76]. In a small series of patients that chemo‐
therapy perfusion was performed with cisplatin (100-150 mg / m) at 42 ° C for 1 h, very good
results were observed. Specifically, the mean survival rate was 18 months (in combination with
radiotherapy and chemotherapy), without serious perioperative complications [89].
In our department, the last three years, we have tried chemotherapy perfusion with peme‐
trexed (500 mg) at 42 ° C for 30 min, after pleurectomy – decortication in seven patients. Their
overall treatment included radiotherapy and systemic chemotherapy (carboplatin and
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pemetrexed). The follow-up of patients continues until today and the results are very encour‐
aging. Worth to mention the case of a patient who has completed three years after the start of
treatment and continues with a very good performance status. Hopefully soon, after comple‐
tion of these patients study (http://clinicaltrials.gov/ct2/show/NCT01409551), the final results
will be published [77].
Photodynamic therapy is a therapeutic method based on the result of the reaction of a
compound containing porphyrin to the effect of visible light. The result of this reaction is the
direct cellular damage and the initiation of cell apoptosis [66]. A study showed that for unclear
reasons, the mean overall survival of patients who have undergone pleurectomy – decortica‐
tion plus photodynamic therapy, is much larger than the group of patients who received
extrapleural pneumonectomy plus photodynamic therapy (8,4 VS 25 months) [83]. Reported
that the combination of pleurectomy – decortication plus photodynamic therapy has compa‐
ratively much greater mean overall survival. Perhaps, this is potentially related to preservation
of the lung or some photodynamic therapy -induced effect, or both [90].
Xenograft experiments has shown that low doses of photodynamic therapy can lead to a
selective and strong uptake of a circulating macromolecular chemotherapeutic drug in human
malignant mesothelioma xenografts, but not in normal tissue [91].
In a recent experimental study in pigs, showed that the use of cold-plasma coagulation may
help in the treatment of mesothelioma. With this technique we can predetermine the depth of
tissue damage (thermo necrosis) from the surface of the lung with the selection of the appro‐
priate dose of energy [92].
13. Conclusion
As for any other type of cancer, the treatment options for malignant pleural mesothelioma
include chemotherapy, irradiation, surgery, immunotherapy or some combination of these
modalities. The choice of treatment is influenced by factors like the extensive nature of this
tumor, its proximity to intrathoracic organs and the general medical condition of these patients
who are usually older and often have underlying diseases. Most patients due to a lack of large
prospective clinical trials are treated in a highly individualized manner. Most reported studies
can at best be classified as phase I type. There are very few properly structured phase II studies
and no phase III studies at all.
The limitations of chemotherapy and radiotherapy have made surgery an important part of
multimodality treatment for MPM. Trimodality therapy has recently emerged as a new
treatment strategy to improve prognosis. To improve resectability rate and local control,
induction chemotherapy is combined with aggressive surgery and post-operative radiother‐
apy. Pemetrexed has been shown to be among the most active agents and is currently used in
induction trials.
Operations for MPM can be divided into two categories – those performed for palliation and
those performed with curative intent. Video-assisted thoracic surgery (VATS) with talc
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pleurodesis is an effective way to control pleural effusions in patients who are not candidates
for further surgical resection. Thoracotomy and partial pleurectomy is necessary only in
situations in which the pleural effusion has loculated and cannot be evacuated by VATS. The
operations performed with curative intent are extrapleural pneumonectomy (EPP) and
pleurectomy – decortication (PD). Surgical treatment can be combined with hyperthermic
pleural chemoperfusion or intrapleural photodynamic therapy.
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